Activity of ertapenem, ciprofloxacin, ceftriaxone, piperacillin-tazobactam, and ampicillin-sulbactam against 12 common clinical isolates of community-acquired bacteremia

Journal of Microbiology, Immunology and Infection

Volumn 42, Issue 5, 2009, Pages 433-438

  Hwang, Kao Pin ^a   Tang, Ya Fen ^a   Shen, Yea Huei ^b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b YUAN'S GENERAL HOSPITAL   (Taiwan)

Author keywords

Anti infective agents; Beta lactamases; Community acquired infections; Microbial sensitivity tests

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; DISK DIFFUSION; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NONHUMAN; TAIWAN;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIA; BACTERIAL TYPING TECHNIQUES; BETA-LACTAMASES; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; MICROBIAL SENSITIVITY TESTS; TAIWAN;

EID: 77749306310     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-10.
2. McCabe WR, Jackson GG. Gram-negative bacteremia 1. Etiology and ecology. Arch Intern Med. 1962;10:847-55.
3. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chamoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA. 1995;274:639-44.
4. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive Care Med. 2001;27(Suppl 1):S33-48.
5. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. Approved standard, M100-S15. Wayne: Clinical and Laboratory Standards Institute; 2005.
6. Performance standards for antimicrobial susceptibility testing. Eleventh informational supplement. NCCLS document M100-S11. Wayne: National Committee for Clinical Laboratory Standards; 2001.
7. Bauernfeind A, Petermuller C. In vitro activity of ciprofloxacin, nofloxacin and nalidixic acid. Eur S Clin Microbiol. 1983;2:11-5.
8. Karas JA, Pillay DG, Muckart D. Treatment failure due to extended-spectrum β-lactamase. J Antimicrob Chemother. 1996;37:203-4.
9. Paterson DL. Recommendation for treatment of severe infection caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000;6:460-3.
10. Niederman MS. Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin. Clin Infect Dis. 2005;41(Suppl 2):S158-66.
11. Burkhardt O, Derendorf H, Welte T. Ertapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother. 2007;8:237-56.
12. Gesser RM, McCarroll K, Teppler H, Woods GL. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J Antimicrob Chemother. 2003;51:1253-60.
13. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003;52:331-44.
14. Mody RM, Erwin DP, Summers AM, Carrero HA, Selby EB, Ewell AJ, et al. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms. Ann Clin Microb Antimicrob. 2007;6:6-10.
15. Hernandez JR, Velasco C, Romero L, Martinez-Martinez L, Pascual A. Comparative in vitro activity of ertapenem against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain. Int Antimicrob Agents. 2006;28:457-9.
16. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A, et al. Antimicrobial susceptibility of the pathogens of bacteremia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Progranme. J Antimicrob Chemother. 2004;53:1018-32.
17. Knothe H, Shah P, Kremery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11:315-7.
18. Pena C, Albareda JM, Pallares R, Pujol M, Tuban F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother. 1995;39:520-4.
19. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Gottberg AV, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000;30:473-8.
20. Livermore DM, Nichols T, Lamagni TL, Potz N, Reynolds R, Duckworth G. Ciprofloxacin-resistant Escherichia coli from bacteraemias in England; increasingly prevalent and mostly from men. J Antimicrob Chemother. 2003;52:1040-2.
21. Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens P, et al. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis. 2002;8:473-8.
22. Everett MJ, Jin YF, Ricci V, Piddock LT. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother. 1996;40:2380-6.
23. Bell JM, Chitsaz M, Turnidge JD, Barton M, Walters LJ, Jones RN. Prevalence and significance of a negative extended-spectrum β-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: result from the SENTRY Asia-Pacific surveillance program. J Antimicrob Chemother. 2007;45:1478-82.
24. Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant Gram-negative clinical pathogens. Antimicrob Agents Chemother. 1997;41:1830-1.
25. Jacoby GA, Mills DM, Chow N. Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48:3203-6.
26. Tsakris A, Ikonomidis A, Poulou A, Spanakis N, Pournaras S, Markou F. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-β-lactamase. J Antimicrob Chemother. 2007;60:136-9.
27. Miriagon V, Tassios PT, Legakis NJ, Tzouvelekis LS. Extended-spectrum cephalosporin resistance in non-typhoid Salmonella. Int J Antimicrob Agents. 2004;23:547-55.
28. Lee SC, Huang SS, Lee CW, Fung CP, Lee N, Shieh WB, et al. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan. BMC Infect Dis. 2007;7:79-83.
29. Kno KC, Shen YH, Hwang KP. Clinical implications and risk factors of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection in children: a case-control retrospective study in a medical center in southern Taiwan. J Microbiol Immunol Infect. 2007;40:248-54.